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Introduction
An important group of critically ill patients in intensive care
units (ICUs) are those exhibiting a systemic inflammatory
response caused by extreme stimulation of the immune
system. Etiologic factors include micro-organisms (sepsis)
and noninfectious insults such as trauma, burns, major
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Abstract
Introduction The present study was conducted to assess the value of serum concentration of
lipopolysaccharide-binding protein (LBP) in patients with systemic inflammatory response syndrome
(SIRS), sepsis and septic shock with respect to its ability to differentiate between infectious and
noninfectious etiologies in SIRS and to predict prognosis.
Methods This prospective cohort study was conducted in a multidisciplinary intensive care unit. Sixty-
eight patients, admitted consecutively to the intensive care unit and who met criteria for SIRS, sepsis
or septic shock were included. Serum LBP was measured using an immunochemiluminiscence assay.
Results Serum levels of LBP were significantly increased in patients with SIRS (n=40; median
30.6µg/ml, range 9.2–79.5µg/ml), sepsis (n=19; median 37.1µg/ml, range 11.8–76.2µg/ml) and
septic shock (n=9; median 59.7µg/ml, range 31.1–105µg/ml), as compared with levels in the healthy
volunteers (5.1±2.2µg/ml; P<0.0001). Serum LBP at study entry was statistically significantly lower
in patients with SIRS than in those with septic shock (P<0.014); no statistically significant difference
existed between patients with SIRS and those with sepsis (P=0.61). Specificity and sensitivity of an
LBP concentration of 29.8 µg/ml to distinguish between infectious and noninfectious etiologies for
SIRS were 50% and 74.2%, respectively. There was no statistically significant difference in LBP
concentration between survivors and nonsurvivors in both groups of patients. Furthermore, in septic
patients the LBP response appeared to exhibit a decreased magnitude.
Conclusion LBP is a nonspecific marker of the acute phase response and cannot be used as a
diagnostic tool for differentiating between infectious and noninfectious etiologies of SIRS.
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surgery, ischemia/reperfusion, and pancreatitis (i.e. systemic
inflammatory response syndrome [SIRS]). Immunopatho-
genetic mechanisms play an important role in the course and
progression of both sepsis and SIRS. Sepsis is frequently an
important factor in the mortality of patients in ICUs.
From a clinical point of view, differentiating between an infec-
tious and a noninfectious etiology in patients with clinical
symptoms of sepsis is very difficult. The limiting factor is the
lack of specificity in differentiating between underlying
causes of inflammation. One of the parameters currently
employed to establish whether sepsis is present is C-reactive
protein (CRP) [1,2]. During the past few years several new
parameters have been introduced, including procalcitonin
and lipopolysaccharide-binding protein (LBP) [3,4].
The acute phase proteins used in diagnostic procedures are
produced mainly by hepatocytes. Two classes of acute phase
proteins may be distinguished on the basis of their synthesis.
Class 1, induced by IL-1 in synergy with IL-6, includes CRP
and MBP. Class 2, induced by IL-6 alone, includes antipro-
teases, α2-macroglobulin, and fibrinogen [5–8].
In 1986, Tobias and coworkers [5] described a new acute
phase reactant, namely LBP. It is a 58kDa protein that is syn-
thesized in the liver, and it potently enhances the sensitivity of
monocytes and granulocytes to lipopolysaccharide (LPS) by
facilitating binding of LPS to the CD14 cell membrane mole-
cule [9,10]. The mature CD14 protein is a myeloid marker
antigen that is expressed on the surface of myeloid cells [11].
CD14 is also found circulating free in plasma, where it is
referred to as soluble CD14; the latter form of CD14 medi-
ates LPS activation of CD14-negative cells, such as endothe-
lial and epithelial cells [12]. LBP catalyzes movement of LPS
monomers from LPS aggregates to high-density lipoprotein
particles [13], leading to neutralization of LPS [12]. LBP
takes part in the transport of other phospholipids by acting as
a lipid exchange protein. Under physiologic circumstances,
LBP binds Gram-negative bacteria via the lipid A part of LPS
[14,15], which mediates its binding to the CD14 cellular
receptor molecule presented by monocytes and
macrophages. This results in the phagocytosis and clearance
of these micro-organisms [16,17]. Binding of endotoxin acti-
vates monocyte/macrophage system cells via Toll-like recep-
tor-4 [18]. The outcome is the production of proinflammatory
cytokines (i.e. IL-1 and tumor necrosis factor-α) [19]. Under
normal circumstances serum levels of LPB vary in the range
5–15µg/ml, but levels increase several fold during the acute
phase response.
After the relationship between LPS and sepsis was unraveled,
the diagnostic and/or prognostic value of LBP levels in patients
with SIRS and sepsis were investigated. Previous studies have
shown elevated LBP levels in patients with Gram-negative
sepsis [20], and elevated LBP levels in patients with SIRS [21]
and in patients with sepsis and septic shock [22].
The primary objective of the present study was to determine
whether LBP can distinguish between infectious and non-
infectious etiologies of SIRS. Secondary objectives were to
assess the relationships between LBP levels and procalci-
tonin, CRP, and clinical, microbiologic, and prognostic para-
meters in sepsis.
Methods
Sixty-eight patients (age range 18–68 years, median
48 years; 42 men, 26 women), who fulfilled the diagnostic cri-
teria for SIRS (40 patients), sepsis (19 patients) or septic
shock (9 patients) [23], were consecutively enrolled between
February 2000 and November 2001.
The diagnostic criteria for SIRS were temperature greater than
38°C or less than 36°C; heart rate greater than
90 beats/minute; respiratory rate greater than 20 breaths/
minute or arterial carbon dioxide tension greater than 32mmHg;
and white blood cell count greater than 12×109/l or less than
4×109/l, or the presence of 10% immature forms.
Sepsis was confirmed by the isolation of an organism consid-
ered to be of pathogenic significance from an otherwise
sterile site (blood, peritoneal cavity, or lung via bronchial
lavage) or by the isolation of an organism of recognized
pathogenic potential from an intravascular catheter removed
for infection related reasons. All patients were screened on a
daily basis for the presence of pathogenic organisms by
blood and urine culture and, where indicated, by biopsy or
aspiration of potentially infected sites.
Septic shock was defined as sepsis with hypotension resis-
tant to fluid resuscitation and evidence of organ hypoperfu-
sion or dysfunction. Specifically, the criteria for septic shock
were hypotension (defined as systolic pressure <90mmHg
or reduced by more than 40mmHg from baseline) and all of
the following criteria: temperature greater than 38°C or less
than 36°C; heart rate greater than 90 beats/minute; respira-
tory rate greater than 30 breaths/min or hyperventilation with
arterial carbon dioxide tension under 32mmHg; white blood
cell count greater than 12×109/l or less than 4×109/l; or the
presence of more than 10% immature cells.
Blood samples were obtained from patients within 24 hours
of meeting the criteria for SIRS, sepsis, or septic shock. All
patients received routine intensive care and resuscitation
therapy. Patients with sepsis and septic shock were given
antibiotic therapy adjusted in accordance with culture results.
The study was approved by the ethics committees of the par-
ticipating hospitals, and written consent was obtained from all
patients or their relatives.
Clinical and functional investigations
The following data were compiled for each patient: demo-
graphic data; Acute Physiology and Chronic Health Evalua-
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tion II score; diagnosis of SIRS, sepsis, or septic shock; the
presence of Gram-negative or Gram-positive infection; and
outcome (mortality).
Laboratory analyses
Blood was obtained in vacutainers (Becton Dickinson, Hei-
delberg, Germany) containing 15% EDTA for blood counts,
and 30U lithium heparin for bilirubin, CRP, alkaline phos-
phatase, and other routine biochemical measurements. For
LBP and procalcitonin, serum was prepared, following coagu-
lation in vacutainer tubes, by centrifugation at 2000g at room
temperature for 20 min. The serum levels of LBP were mea-
sured by means of a commercial chemiluminiscence method
(Immulite DPC; Biermann, Bad Nauhe, Germany). Twenty-
three healthy adult volunteers (age range 18–48 years), who
exhibited no signs of inflammatory or gastrointestinal disease,
served as control individuals. Procalcitonin was measured by
immunoluminometric assay (LUMItest PCT; Brahms Diagnos-
tica GmbH, Berlin, Germany). The cutoff value for procalci-
tonin was 0.5µg/l. We analyzed the levels from study entry,
which was defined as the first 24 hours in which SIRS,
sepsis, and septic shock criteria were met. Twenty-three
patients were assessed repeatedly (12 patients with sepsis,
six patients with SIRS, and five patients with septic shock) at
3- to 5-day intervals for the next 30 days or until death. In the
remaining patients, who either died or were transferred to
other departments, only the baseline investigations were per-
formed. Altogether 138 measurements were completed. Confir-
mation of diagnosis was done retrospectively with the
knowledge of microbiologic findings. The levels of serum pro-
teins were compared with levels in healthy volunteers, SIRS
patients, and patients with sepsis and septic shock; they were
also compared between survivors and non-survivors.
Statistical analysis
Normal distribution of data was checked for each variable
using the Kolmogorov–Smirnov test. The results are
expressed as either a mean and standard deviation, or as a
median with range. Significance testing of between group dif-
ferences was performed using the Student’s t-test and
Mann–Whitney test. Changes in serum concentrations of
LBP, procalcitonin, and CRP over time were compared using
the Kruskal–Wallis test. To evaluate correlations, Spearman’s
rank correlation coefficient was used. P<0.05 was consid-
ered statistically significant.
Results
Sixty-eight patients consecutively admitted to the interdiscipli-
nary ICU were enrolled in the study upon meeting criteria for
SIRS, sepsis, or septic shock. The demographic data and
clinical parameters of patients are summarized in Table 1. In
addition, 23 adult healthy volunteers (age range 18–48 years)
served as control individuals.
The observed mortality in patients with SIRS was 15%
(6/40), that in patients with sepsis was 57.9% (11/19), and
that in patients with septic shock was 89% (8/9). Pneumonia
was the leading cause of sepsis (57%), and refractory septic
shock and multiple organ dysfunction syndrome were the
immediate causes of death. During hospitalization, eight
patients with SIRS developed sepsis, and in four patients
sepsis changed to septic shock.
Levels of lipopolysaccharide-binding protein at the
study entry
The mean serum concentration of LBP in all groups of
patients was significantly greater than in control individuals
(P<0.0001); in ascending order, the levels were 30.6µg/ml
in patients with SIRS, 37.1µg/ml in those with sepsis, and
59.7µg/ml in those with septic shock. The difference
between levels in patients with SIRS and those with septic
shock was statistically significant (P<0.01).
The specificity and sensitivity of serum LBP concentration in
differentiating between patients with SIRS and those with
sepsis/septic shock (with cutoff set at 29.8µg/ml) were poor,
at 50% and 74.2%, respectively. Serum LBP at study entry
did not differ between patients with Gram-negative
(43.1±21.3µg/ml) and Gram-positive infections
(45.2±19.8µg/ml).
There was no significant difference between serum LBP in
survivors and nonsurvivors in the group of patients with SIRS,
or in the group of patients with sepsis and septic shock
(P=0.69 and P=0.61, respectively). There was no correla-
tion between serum LBP and clinical status according to
Acute Physiology and Chronic Health Evaluation II (Spear-
man’s rho 0.199; P=0.278). LBP serum levels did not differ
between patients with positive and those with negative blood
cultures (42.1±21.4µg/ml versus 39.5±18.1µg/ml). LBP
levels were not associated with hepatic dysfunction, as
defined by bilirubinemia >50µmol/l (Spearman’s
rho=–0.125; P=0.36).
The mean serum concentrations of LBP, CRP and procalci-
tonin are listed in Table 2. There was only a weak correlation
between LBP and CRP in the group of patients with sepsis
and septic shock, and in survivors (Table 3).
Trends in lipopolysaccharide-binding protein levels
during the course of hospitalization
The dynamics of LBP levels in surviving and nonsurviving
patients with sepsis were similar. The higher levels seen at
the first examination decreased thereafter and were lowest at
the last examination, despite the temporary increase seen in
some patients who did not survive sepsis (Fig.1). The differ-
ence between the first and last examination was statistically
significant (in survivors, median 25.4µg/ml versus 11.9µg/ml
[P=0.009]; in nonsurvivors, median 41.8µg/ml versus
26.4µg/ml [P=0.010]; Fig.2). LBP levels at the last examina-
tion were significantly different between survivors and nonsur-
vivors (P=0.014).R157
Discussion
The present study showed that serum LBP levels in patients
with SIRS, sepsis, or septic shock were higher than those in
healthy volunteers. Myc and coworkers [21] reported similar
findings. We found no difference in LBP levels at study entry
between patients with SIRS of noninfectious etiology and
patients with sepsis; neither did we find any difference in LBP
levels between surviving and nonsurviving patients with SIRS,
or any significant difference in the group of patients with
sepsis or septic shock. However, during the follow up of
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Table 2
Serum lipopolysacharide-binding protein, procalcitonin, and C-reactive protein at study entry (baseline measurement)
n LBP (µg/ml) PCT (ng/ml) CRP (mg/l)
SIRS 40 30.6 (9.2–79.5) 0.6 (0.05–2.5) 56.5 (15.2–136.8)
Sepsis 19 37.1 (11.8–76.2) 6.1 (1.4–89.8) 157.1 (41.6–245)
Septic shock 9 59.7 (31.1–105) 25.6 (4.6–85.6) 211.0 (83.3–280)
Data are expressed as median (range). CRP, C-reactive protein; LBP, lipopolysacharide-binding protein; PCT, procalcitonin; SIRS = systemic
inflammatory response syndrome.
Table 3
Correlations of lipopolysaccharide-binding protein (LBP) with procalcitonin, and of LBP with C-reactive protein at study entry
(baseline measurement)
LBP + PCT LBP + CRP
rP rP
SIRS (noninfectious etiology; n=40) 0.23 0.19 –0.046 0.79
Sepsis + septic shock (infectious etiology; n=28) 0.35 0.046 0.54 0.002
Survivors (n=43) 0.27 0.054 0.22 0.14
Nonsurvivors (n=25) 0.22 0.32 0.58 0.004
Shown are Pearson‘s correlation coefficients along with corresponding P values. SIRS, systemic inflammatory response syndrome.
Figure 1
Time course of lipopolysaccharide-binding protein (LBP) levels in
surviving and nonsurviving patients with sepsis and septic shock.
Shown are data from patients available for follow up, who were
assessed repeatedly at 3- to 5-day intervals for 30 days or until death.
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Table 1
Demographic characteristics of patients
Parameter Value
Age (years; median [range])
SIRS 49.7 (24–73)
Sepsis and septic shock 45.2 (21–66)
Sex ratio (male:female) 42:26
APACHE II score (median [range]) 18.2 (13–28)
Focus (n=28)
Pneumonia 16
Peritonitis 5
Empyema 1
Mediastinitis 2
Endocarditis 2
Isolated positive blood culture 2
Causative microorganisms
Gram negative 15
Gram positive 10
Fungus 3
Positive blood cultures (n [%]) 11 (39.3)
APACHE = Acute Physiology and Chronic Health Evaluation; SIRS =
systemic inflammatory response syndrome. R158
these patients, the nonsurviving septic patients had higher
LBP levels than did the surviving patients, which is in accor-
dance with the findings reported by Carroll and coworkers
[20] and by Schumann and coworkers [24] but not with
those reported by Opal and coworkers [22].
In a surveillance study of several hundred patients, Carroll
and coworkers [20] demonstrated a wide range of inflamma-
tory diseases or conditions in which the levels of LBP were
elevated (i.e. sepsis, meningococcemia, abdominal infection,
and inflammatory bowel disease) and unchanged (i.e. sys-
temic lupus erythematosus, rheumatoid arthritis, and acute
graft versus host disease). That study also showed that ele-
vated levels of LBP (>46µg/ml) at study entry in patients
with suspected Gram-negative sepsis were associated with
significantly greater mortality. This suggests an association
between LBP levels with severity of disease. Severity of
disease would be expected to occur in conjunction with
increased endotoxin in the systemic circulation. Endotoxemia
may originate from regional hypoperfusion and mucosal
ischemia, which was suggested to promote translocation of
endotoxin to the systemic circulation [25]. In the present
study we did not perform measurements of endotoxin and so
we are unable to assess its correlation with LBP levels.
Opal and coworkers [22] also did not find any such correla-
tion, but they reported significantly lower serum LBP levels in
nonsurvivors than in survivors within 24 hours of onset of
sepsis. They hypothesized that synthesis of LBP fails in the
presence of rapidly progressive septic shock. Carroll and
coworkers [26] reported data from additional clinical trials
suggesting that LBP is elevated in patients with hemorrhagic
trauma or cystic fibrosis, as well as in patients with partial
hepatectomy, and concluded that these patients were sys-
temically exposed to bacteria and endotoxin. In the present
study we did not find any relationship between LBP and
hepatic function, as indicated by bilirubinemia.
Similar to Froon and coworkers [27], we observed no differ-
ence between LBP levels in patients with Gram-negative and
those with Gram-positive infections.
The dynamics of LBP levels in surviving and nonsurviving
patients with sepsis were interesting. In both groups of
patients, the higher LBP levels seen at the first examination
decreased thereafter and were lowest at the last examination.
This cannot be explained by hepatic failure because in the
survivors hepatic function recovered, but the phenomenon
could be due to anergy or tolerance to a long-lasting insult, in
this case endotoxin or infection.
We found initial LBP levels to have low specificity and sensi-
tivity in distinguishing between sepsis and SIRS. This conclu-
sion is consistent with earlier reports that LBP is a marker of
overall inflammation (i.e. SIRS or multiple organ dysfunction
syndrome) [28]. It is possible that patients with sepsis were
erroneously classified as having SIRS because of limitations
in currently used diagnostic methods. LBP levels have been
shown to increase in hemorrhagic colitis and hemolytic
uremic syndrome [29]. We found no correlation between
LBP and procalcitonin or CRP in any diagnostic group of
patients, and neither were the LBP serum levels correlated
with illness severity scores.
Conclusion
In conclusion, LBP is a nonspecific marker of the acute phase
response and cannot be used as a diagnostic tool for differenti-
ating between infectious and noninfectious etiologies of SIRS.
This conclusion is supported by our observation of similar LBP
serum levels in patients with SIRS and in those with sepsis.
The dynamics of LBP levels (followed in 17 patients) suggest
that the LBP levels in septic patients decrease over the course
or at the end of the disease. However, the course of LBP levels
in individual patients is variable.
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